Background The treatment of in-stent restnosis (ISR) remains a therapeutic challenge, since many pharmachologic and mechanical approaches have shown disappointing results. The drug eluting stent (DES) has been reported to be effective in de-novo coronary lesions. The objective of this study was to assess the value of DESs including sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) implantation in patients with ISR. Methods In a multi-center cohort of consecutive patients treated with DES between April 2003 and May 2004, 62 patients (age 61.9짹8.2 years, female 22.4%) receiving DESs for the treatment of ISR were enrolled. They were treated with 1 or 2 DESs. Clinical outcomes and angiographical follow-up data at 6 months were investigated. The primary end point was the incidence of major adverse cardiac events (MACE). The secondary end point was angiographic restenosis. Results In quantitative coronary angiography, lesion length was 21.1짹9.4mm, reference diameter was 2.9짹0.5 mm and minimal luminal diameter (MLD) was 0.6짹0.5 mm. Post-stenting MLD was 2.8짹0.5 mm. 47 SESs and 20 PESs were implanted at 64 lesions. The procedures were technically successful in all cases. The subsets of stented lesions were DM (n=26, 40.6%), diffuse long lesion > 30 mm (n=10, 15.6%), overlapping stented lesion (n=5, 7.8%), small vessel <2.75 mm (n=22, 34.3%), Preliminary clinical and angiographical results are as follows: At 6 month clinical follow-up, the MACE rate was 16% (10 patients; 2 MI, 8 TLR [4 SES, 4 PES]). Six-month angiographic ISR was 40% (14/35 lesions; 8 SES, 6 PES). Follow-up MLD was 1.8짹 1.1mm and late loss was 1.0+0.8mm. Final clinical and angiographic results will be presented at the scientific meeting. Conclusion Drug-eluting stent implantation is considered safe and potentially efficacious in the treatment of ISR.